303 related articles for article (PubMed ID: 33225317)
1. Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury.
Tabassum N; Zhang H; Stebbing J
Cell Rep Med; 2020 Nov; 1(8):100145. PubMed ID: 33225317
[TBL] [Abstract][Full Text] [Related]
2. A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury.
Kost-Alimova M; Sidhom EH; Satyam A; Chamberlain BT; Dvela-Levitt M; Melanson M; Alper SL; Santos J; Gutierrez J; Subramanian A; Byrne PJ; Grinkevich E; Reyes-Bricio E; Kim C; Clark AR; Watts AJB; Thompson R; Marshall J; Pablo JL; Coraor J; Roignot J; Vernon KA; Keller K; Campbell A; Emani M; Racette M; Bazua-Valenti S; Padovano V; Weins A; McAdoo SP; Tam FWK; Ronco L; Wagner F; Tsokos GC; Shaw JL; Greka A
Cell Rep Med; 2020 Nov; 1(8):100137. PubMed ID: 33294858
[TBL] [Abstract][Full Text] [Related]
3. A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic.
Alimova M; Sidhom EH; Satyam A; Dvela-Levitt M; Melanson M; Chamberlain BT; Alper SL; Santos J; Gutierrez J; Subramanian A; Grinkevich E; Bricio ER; Kim C; Clark A; Watts A; Thompson R; Marshall J; Pablo JL; Coraor J; Roignot J; Vernon KA; Keller K; Campbell A; Emani M; Racette M; Bazua-Valenti S; Padovano V; Weins A; McAdoo SP; Tam FWK; Ronco L; Wagner F; Tsokos GC; Shaw JL; Greka A
bioRxiv; 2020 Jun; ():. PubMed ID: 32637960
[TBL] [Abstract][Full Text] [Related]
4. Fostamatinib: A Review in Chronic Immune Thrombocytopenia.
Paik J
Drugs; 2021 Jun; 81(8):935-943. PubMed ID: 33970459
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.
Sahebnasagh A; Saghafi F; Safdari M; Khataminia M; Sadremomtaz A; Talaei Z; Rezai Ghaleno H; Bagheri M; Habtemariam S; Avan R
J Clin Pharm Ther; 2020 Dec; 45(6):1515-1519. PubMed ID: 32860252
[TBL] [Abstract][Full Text] [Related]
6. Repurposing Multiple-Molecule Drugs for COVID-19-Associated Acute Respiratory Distress Syndrome and Non-Viral Acute Respiratory Distress Syndrome via a Systems Biology Approach and a DNN-DTI Model Based on Five Drug Design Specifications.
Ting CT; Chen BS
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409008
[TBL] [Abstract][Full Text] [Related]
7. Could SARS-CoV-2-induced lung injury be attenuated by vitamin D?
Xiao D; Li X; Su X; Mu D; Qu Y
Int J Infect Dis; 2021 Jan; 102():196-202. PubMed ID: 33129966
[TBL] [Abstract][Full Text] [Related]
8. A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19.
Sahebnasagh A; Mojtahedzadeh M; Najmeddin F; Najafi A; Safdari M; Rezai Ghaleno H; Habtemariam S; Berindan-Neagoe I; Nabavi SM
Arch Med Res; 2020 Oct; 51(7):631-635. PubMed ID: 32863034
[TBL] [Abstract][Full Text] [Related]
9. Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions.
Root-Bernstein R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672738
[TBL] [Abstract][Full Text] [Related]
10. Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?
Saha S; Halder AK; Bandyopadhyay SS; Chatterjee P; Nasipuri M; Bose D; Basu S
Methods; 2022 Jul; 203():564-574. PubMed ID: 34455072
[TBL] [Abstract][Full Text] [Related]
11. Natural product derived phytochemicals in managing acute lung injury by multiple mechanisms.
He YQ; Zhou CC; Yu LY; Wang L; Deng JL; Tao YL; Zhang F; Chen WS
Pharmacol Res; 2021 Jan; 163():105224. PubMed ID: 33007416
[TBL] [Abstract][Full Text] [Related]
12. Mucin 1 Inhibits Ferroptosis and Sensitizes Vitamin E to Alleviate Sepsis-Induced Acute Lung Injury through GSK3
Wang YM; Gong FC; Qi X; Zheng YJ; Zheng XT; Chen Y; Yang ZT; Qing-Ye ; Mao EQ; Chen EZ
Oxid Med Cell Longev; 2022; 2022():2405943. PubMed ID: 35910848
[TBL] [Abstract][Full Text] [Related]
13. Elastase Inhibitor Cyclotheonellazole A: Total Synthesis and In Vivo Biological Evaluation for Acute Lung Injury.
Cui Y; Zhang M; Xu H; Zhang T; Zhang S; Zhao X; Jiang P; Li J; Ye B; Sun Y; Wang M; Deng Y; Meng Q; Liu Y; Fu Q; Lin J; Wang L; Chen Y
J Med Chem; 2022 Feb; 65(4):2971-2987. PubMed ID: 35005973
[TBL] [Abstract][Full Text] [Related]
14. Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia.
Newland A; McDonald V
Immunotherapy; 2020 Dec; 12(18):1325-1340. PubMed ID: 33023353
[TBL] [Abstract][Full Text] [Related]
15. Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic.
Strich JR; Ramos-Benitez MJ; Randazzo D; Stein SR; Babyak A; Davey RT; Suffredini AF; Childs RW; Chertow DS
J Infect Dis; 2021 Mar; 223(6):981-984. PubMed ID: 33367731
[TBL] [Abstract][Full Text] [Related]
16. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop.
Yaqinuddin A; Kashir J
Med Hypotheses; 2020 Oct; 143():109906. PubMed ID: 32505910
[TBL] [Abstract][Full Text] [Related]
17. A Case Report for Using Methylprednisolone for Severe ARDS Caused by SARS-CoV-2 Delta Variant in a Pediatric Patient With Lennox-Gastaut Syndrome.
Park E; You J
J Korean Med Sci; 2022 Mar; 37(10):e82. PubMed ID: 35289141
[TBL] [Abstract][Full Text] [Related]
18. Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial.
Strich JR; Tian X; Samour M; King CS; Shlobin O; Reger R; Cohen J; Ahmad K; Brown AW; Khangoora V; Aryal S; Migdady Y; Kyte JJ; Joo J; Hays R; Collins AC; Battle E; Valdez J; Rivero J; Kim IH; Erb-Alvarez J; Shalhoub R; Chakraborty M; Wong S; Colton B; Ramos-Benitez MJ; Warner S; Chertow DS; Olivier KN; Aue G; Davey RT; Suffredini AF; Childs RW; Nathan SD
Clin Infect Dis; 2022 Aug; 75(1):e491-e498. PubMed ID: 34467402
[TBL] [Abstract][Full Text] [Related]
19. Protective and predictive role of Mucin1 in sepsis-induced ALI/ARDS.
Wang YM; Qi X; Gong FC; Chen Y; Yang ZT; Mao EQ; Chen EZ
Int Immunopharmacol; 2020 Jun; 83():106438. PubMed ID: 32247267
[TBL] [Abstract][Full Text] [Related]
20.
Mardi A; Meidaninikjeh S; Nikfarjam S; Majidi Zolbanin N; Jafari R
Viral Immunol; 2021 Dec; 34(10):679-688. PubMed ID: 34882013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
